Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases

Fragoulis, G. E., Siebert, S. and McInnes, I. B. (2016) Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annual Review of Medicine, 67(1), pp. 337-353. (doi: 10.1146/annurev-med-051914-021944) (PMID:26565676)

Full text not currently available from Enlighten.


The discovery of the biological functions of the interleukin-23/-17 axis led to the identification of IL-23 and IL-17 as important participants in the pathogenesis of several immune-mediated diseases. Therapeutic agents targeting these cytokines and/or their receptors have now been developed as potential treatment strategies for common immune-mediated diseases. Anti-IL-17 and anti-IL-12/-23 regimens appear particularly effective in psoriasis, with promising results in spondyloarthropathies also emerging. Overall, these agents appear well tolerated, with adverse-event rates that are commensurate with those in other biologic treatment programs. The strategic utility of these new agents, however, remains uncertain, and further studies will be required to determine their place in the context of existing conventional and biologic immune-modifying agents.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Fragkoulis, Dr Georgios and Siebert, Professor Stefan
Authors: Fragoulis, G. E., Siebert, S., and McInnes, I. B.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Annual Review of Medicine
Publisher:Annual Reviews
ISSN (Online):1545-326X

University Staff: Request a correction | Enlighten Editors: Update this record